

Listing of Claims

Please cancel claims 58-64. Please add new claims 65-69.

1. (previously presented) A method for administering a therapeutic medium to a posterior segment of an eye, the method comprising the step of:

instilling the therapeutic medium sub-retinally; wherein said instilling comprises injecting a solution including the therapeutic medium directly in the sub-retinal space; wherein the step of instilling includes localizing the action of the therapeutic medium at the choroid and the retina and minimizing action at other tissues of the eye.

2. (canceled)

3. (original) The administering method of claim 1, wherein the therapeutic medium being administered is one of a drug, medicament, antiproliferative, neuroprotective, steroidal anti-inflammatory, non-steroidal anti-inflammatory, growth factor, neurotropic factor, antiangiogenic, thrombolytic or a gene.

4. (previously presented) The administering method of claim 3, wherein the steroidal anti-inflammatory is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

5. (original) The administering method of claim 1, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

6. (original) The administering method of claim 1, wherein said step of instilling includes forming a depot of a drug between the choroid and the retina.

7. (canceled)

8. (previously presented) The administering method of claim 1, wherein said step of instilling includes injecting a solution including the therapeutic medium between the choroid and the retina.

9-10. (canceled)

11. (original) The administering method of claim 1, wherein said step of instilling includes: creating a localized retinal detachment to define a sub-retinal space; and disposing the therapeutic medium in the sub-retinal space formed by the localized retinal detachment.

12-19. (canceled).

20. (previously presented) A method for treating an eye, comprising the step of: administering a therapeutic medium to a posterior segment of an eye sub-retinally; wherein said administering comprises (a) forming a sub-retinal space; and (b) injecting a solution including the therapeutic medium in the sub-retinal space.

21-26. (canceled)

27. (previously presented) The eye treatment method of claim 20, further comprising the step of controllably releasing over time the sub-retinally administered therapeutic medium.

28-29. (canceled)

30. (previously presented) The administering method of claim 20, wherein said step of injecting includes localizing the action of the steroid at the choroid and the retina and minimizing action at other tissues of the eye.

31-64. (canceled)

65. (new) A method for administering a therapeutic medium to a posterior segment of an eye having a retina, the method comprising the step of:

providing a sustained release delivery device in the form of a filament; wherein an end of the device is configured to easily penetrate tissue of the retina; and

implanting the delivery device sub-retinally by aiming the end configured to penetrate the retina toward the retina and implanting the device; wherein said step of implanting includes localizing the action of the therapeutic medium at the choroid and the retina and minimizing action at other tissues of the eye.

66. (new) The administering method of claim 65, wherein the therapeutic medium being administered is one of a drug, medicament, antiproliferative, neuroprotective, steroidal anti-inflammatory, non-steroidal anti-inflammatory, growth factor, neurotropic factor, antiangiogenic, thrombolytic or a gene.

67. (new) The administering method of claim 66, wherein the steroidal anti-inflammatory is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

68. (new) The administering method of claim 65, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

69. (new) The administering method of claim 65, wherein the sustained release device is configured to provide a sustained sub-retinal release of the therapeutic medium.